Prognostic Models for Phase I Clinical Trials

Purpose: To evaluate a cancer patient for participation in a Phase I clinical trial using the models of Olmos et al (EDDN models).

Info MyLikes MyPaths

Evaluation

Are you evaluating a cancer patient for a Phase I clinical trial?

Yes

Number of metastatic sites

Serum albumin

Serum LDH

IU/L

Upper limit of normal for serum LDH

IU/L

Serum alkaline phosphatase

IU/L

Upper limit of normal for serum alkaline phosphatase

IU/L

White blood cell count

Percent lymphocytes in the differential count (enter from 0 to 100)

Number of weeks per treatment

ECOG performance status

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Total for model A

Median survival in weeks by model A

Total for model B

Median survival in weeks by model B

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Diagnosis

Risk Factors
Clinical Diagnosis, Including Family History For Genetics
Laboratory Tests
- Advanced Cancer Vitamin B12 to C-Reactive Protein (CRP) Ratio
Criteria For Diagnosis
- San Diego Severity Index (SDSI) for Patients with Terminal Cancer
- Models for Predicting Survival in Patient with Advanced Cancer
Severity, Prognosis, Stage
Complications
- San Diego Severity Index (SDSI) for Patients with Terminal Cancer
- Models for Predicting Survival in Patient with Advanced Cancer

Therapy

Interventional Radiology
- Survival Model for Patient Undergoing Radiotherapy for Metastatic Spinal Cord Compression

Monitoring

Response To Therapy
- Survival Model for Patient Undergoing Radiotherapy for Metastatic Spinal Cord Compression
Disease Progression
- Predictors for Early Death of Older Adult Starting Cancer Chemotherapy

Patient Concerns

End-of-life, Palliative Care

Specialty

Hematology Oncology
Surgery, general

Objective

severity
prognosis
stage
selection
response to therapy

ICD-10

C00-C14 - Malignant neoplasms of lip, oral cavity and pharynx
C15-C26 - Malignant neoplasms of digestive organs
C30-C39 - Malignant neoplasms of respiratory and intrathoracic organs
C40-C41 - Malignant neoplasms of bone and articular cartilage
C43-C44 - Melanoma and other malignant neoplasms of skin
C45-C49 - Malignant neoplasms of mesothelial and soft tissue
C50-C50 - Malignant neoplasm of breast
C51-C58 - Malignant neoplasms of female genital organs
C60-C63 - Malignant neoplasms of male genital organs
C64-C68 - Malignant neoplasms of urinary tract
C69-C72 - Malignant neoplasms of eye, brain and other parts of central nervous system
C73-C75 - Malignant neoplasms of thyroid and other endocrine glands
C76-C80 - Malignant neoplasms of ill-defined, secondary and unspecified sites
C81-C96 - Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissu
C97-C97 - Malignant neoplasms of independent (primary) multiple sites

Info

Purpose: To evaluate a cancer patient for participation in a Phase I clinical trial using the models of Olmos et al (EDDN models).

Specialty: Hematology Oncology, Surgery, general

Objective: severity, prognosis, stage, selection, response to therapy

ICD-10: C00-C14, C15-C26, C30-C39, C40-C41, C43-C44, C45-C49, C50-C50, C51-C58, C60-C63, C64-C68, C69-C72, C73-C75, C76-C80, C81-C96, C97-C97,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path